BioBridgeX
Log inCompare quotes
Modality

Cell Therapy (CAR-T / NK / TIL) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a cell therapy (CAR-T, NK, or TIL) program means contracting specialists for vector supply, process and analytical development, GMP autologous or allogeneic manufacturing, potency and release testing, and regulatory CMC support. BioBridgeX is the neutral marketplace: free for buyers, where you compare quotes and contract directly with every supplier you engage, in one place.

Cell Therapy (CAR-T / NK / TIL) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Cell Therapy (CAR-T / NK / TIL) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Cell Therapy (CAR-T / NK / TIL) drug?

Cell therapy is the hardest CMC problem in the modality landscape, and the work spreads across more suppliers than most teams expect at the outset. On the discovery and preclinical side you are validating a construct (the CAR design, the costimulatory domains, the cell source), running in vitro potency and cytotoxicity assays, and pushing toward IND-enabling tox in a relevant model. Cell products do not behave like small molecules in tox studies, so you often need a CRO that has actually run studies on a living cell drug rather than one that treats it as another biologic.

The center of gravity, though, is manufacturing. An autologous CAR-T process starts from a patient apheresis, runs through activation, viral transduction, expansion, formulation, and cryopreservation, and every one of those steps has to be locked down, characterized, and made reproducible across operators and sites. Allogeneic NK and TIL programs change the math: you are building a scalable, donor-derived or expanded process where consistency across a much larger batch matters more than turnaround on a single patient. Either way you need vector. Most CAR-T and many gene-modified NK programs depend on a lentiviral or retroviral vector, which means a viral vector manufacturing slot (and the plasmid DNA upstream of it) is on your critical path long before you reach clinical supply.

This is where specialist CDMOs separate from generalists. A generalist biologics shop can run a bioreactor and fill vials; far fewer have validated, GMP-grade closed-system cell processing, cryo logistics, a chain-of-identity and chain-of-custody system tying a product back to the right patient, and the potency and flow-based release panels regulators now expect for a cell drug. Analytical capability is the quiet differentiator: vector copy number, transduction efficiency, viability, identity, sterility, mycoplasma, endotoxin, and a potency assay that actually predicts clinical activity. A supplier that has filed this package before, and survived the agency questions that come with it, saves you months you cannot get back.

How do you choose a CRO or CDMO for Cell Therapy (CAR-T / NK / TIL)?

Supplier selection for cell therapy rewards specificity. The right partner for an autologous CAR-T is often the wrong one for an allogeneic NK platform, so screen against your exact process, scale, and regulatory path rather than a generic capability list. Use the checklist below as a starting screen, then go deep with the two or three suppliers that survive it.

  • Relevant platform and track record: have they run your specific format (autologous CAR-T, allogeneic NK, TIL) through process development and GMP, not just adjacent gene therapy work? Ask for the cell types and constructs they have actually handled.
  • GxP and analytical capability for this modality: validated GMP cleanrooms or closed/isolator systems, plus an analytical team that owns vector copy number, transduction efficiency, viability, identity, sterility, mycoplasma, and a real potency assay, not outsourced piecemeal.
  • Vector and starting-material supply: in-house or reliably sourced lentiviral or retroviral vector and plasmid DNA, with timeline and slot availability that fits your clinical schedule, since vector lead times often dominate the program.
  • Capacity and scale: enough suites and cryo capacity to run your batch cadence today and a credible path to commercial scale, whether that is many small autologous runs or fewer large allogeneic lots.
  • Regulatory experience: prior INDs, BLAs, or comparable filings for cell products, familiarity with FDA and EMA expectations for potency and comparability, and the ability to author or support the CMC sections rather than hand you raw data.
  • Chain of identity and logistics: a documented chain-of-identity and chain-of-custody system, cryopreservation and cold-chain handling, and apheresis or starting-material coordination that will not break under clinical timelines.
  • IP and data ownership: clear terms that your process know-how, cell lines, and analytical methods remain yours, with no claim on your construct or downstream rights.

Frequently asked questions

Do I need separate suppliers for vector and cell manufacturing, or can one CDMO do both?
Some larger cell therapy CDMOs offer both viral vector and drug-product manufacturing under one roof, which simplifies tech transfer and comparability. Many programs still split them, sourcing lentiviral or retroviral vector from a dedicated vector house and running cell processing elsewhere. Both models work. The split adds an interface to manage but widens your options on capacity and price. On BioBridgeX you can engage a single integrated CDMO or a vector supplier plus a separate manufacturer and still compare quotes and contract directly with each chosen supplier in one place.
What is the difference between sourcing for an autologous CAR-T versus an allogeneic NK or TIL program?
Autologous is a one-patient, one-batch problem: turnaround time, chain of identity, and apheresis logistics dominate, and you need many short reproducible runs. Allogeneic NK and TIL programs are a scale and consistency problem: larger donor-derived or expanded lots, banking, and batch-to-batch comparability matter more than single-run speed. A CDMO strong in one is not automatically strong in the other, so screen suppliers against your specific format rather than a generic cell therapy label.
How early should I lock in a cell therapy manufacturing slot?
Earlier than feels comfortable. GMP cell therapy and viral vector capacity is genuinely constrained, and vector lead times alone can run many months. Teams that wait until process development is finished often find the slot they wanted is booked, which pushes the whole clinical timeline. A practical pattern is to start supplier conversations during late preclinical, secure vector and a manufacturing slot in parallel, and treat capacity as a critical-path item rather than a procurement afterthought.
Who owns my construct, process, and data when I outsource to a CDMO?
Your construct, cell lines, process know-how, and analytical methods should remain entirely yours. A well-structured agreement gives the CDMO a license to perform the work and nothing more, with no claim on your IP or downstream rights. Cell therapy contracts get complicated because process and product blur together, so read the background-IP and improvements clauses carefully. BioBridgeX contracts are written so the buyer keeps ownership of study data and IP by default.
Is BioBridgeX really free for buyers, and how does the pricing work?
Yes. Buyers pay no platform fee to source, compare, or contract through BioBridgeX. We act as the neutral marketplace and charge a flat 2 percent fee to the supplier, deducted before disbursement, so it does not sit on top of your quote. You see supplier pricing directly and compare quotes, then contract directly with each chosen supplier in one place.
Can I run my whole cell therapy program, from preclinical CRO work through GMP supply, on one platform?
Yes. BioBridgeX covers the full path: discovery and preclinical CROs, IND-enabling toxicology, viral vector and plasmid DNA manufacturing, GMP cell therapy manufacturing, and analytical and release testing, across all indications and modalities. You can mix specialist suppliers for each step and still compare quotes and contract directly with each chosen supplier in one place, and the buyer pays the supplier directly.

Source Cell Therapy (CAR-T / NK / TIL) work with one contract

Compare transparent quotes from qualified Cell Therapy (CAR-T / NK / TIL) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes